Valuation : Amicus Therapeutics, Inc.

Market Cap 4.55B 3.92B 3.68B 3.36B 6.29B 430B 6.31B 43.53B 16.89B 220B 17.09B 16.71B 710B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.04B 3.8B 3.48B 6.5B 444B 6.52B 44.95B 17.44B 228B 17.64B 17.26B 733B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
6 months+1.12%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 7.61
Extreme 7.61
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
4/27/26 Issuer sale

General Counsel

1,264,993 0.4029%
4/27/26 Issuer sale

Director

395,940 0.1261%
4/27/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+81.35%+14.55% 4.55B
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.81%+0.50%+74.86%+99.07% 27.95B
Weighted average by Cap. -1.01%+0.11%+89.28%+125.96%

Financials

2024 2025
Net sales 528M 455M 428M 391M 731M 49.88B 733M 5.05B 1.96B 25.59B 1.98B 1.94B 82.44B 634M 546M 513M 469M 877M 59.88B 880M 6.07B 2.35B 30.72B 2.38B 2.33B 98.97B
Net income -56.11M -48.28M -45.42M -41.49M -77.62M -5.3B -77.84M -537M -208M -2.72B -211M -206M -8.76B -27.11M -23.33M -21.95M -20.05M -37.51M -2.56B -37.61M -259M -101M -1.31B -102M -99.58M -4.23B
Net Debt 194M 167M 157M 143M 268M 18.29B 269M 1.85B 719M 9.38B 727M 711M 30.23B 149M 128M 120M 110M 206M 14.05B 206M 1.42B 553M 7.21B 559M 547M 23.23B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock